Peptide legal status tracker
Where each peptide stands with the FDA, in plain English, and what the July 2026 advisory vote did and didn’t change.
Last checked October 31, 2026. Rules can change quickly; check the date before relying on this.
The short version: none of these peptides is FDA-approved, and none can legally be compounded by a pharmacy today.
In July 2026, an FDA advisory committee recommended that six of them be allowed for pharmacy compounding. That recommendation is not a rule. The FDA still has to propose and finalize one, and there is no deadline for it to act. Products sold as “research use only” are outside the regulated drug system entirely.
| Peptide | Committee vote (July 2026) | Legal to compound today? |
|---|---|---|
| BPC-157free base and acetate | Recommended, 8 to 6 with 1 abstention. Reviewed for ulcerative colitis, not for tendons or joints. | No |
| KPV | Recommended, 8 to 6 with 1 abstention. | No |
| TB-500 | Recommended, 8 to 6 with 1 abstention. | No |
| MOTS-c | Recommended, 7 to 5 with 2 abstentions. | No |
| Epitalon | Recommended. | No |
| Semax | Recommended. | No |
| Peptide | Committee vote (July 2026) | Legal to compound today? |
|---|---|---|
| Emideltidealso called DSIP | Voted against, 7 to 6 with 1 abstention. | No |
| Peptide | Status | Legal to compound today? |
|---|---|---|
| GHK-Cuinjectable | Committee review scheduled before the end of February 2027. | No |
| Dihexa acetate | Committee review scheduled before the end of February 2027. | No |
| LL-37cathelicidin | Committee review scheduled before the end of February 2027. | No |
| PEG-MGF | Committee review scheduled before the end of February 2027. | No |
| Melanotan II | Committee review scheduled before the end of February 2027. | No |
How a peptide becomes legal to compound
- Taken off the “significant safety concerns” listDone for all twelve in April 2026. This removed a red flag but did not make them legal to compound.
- Advisory committee voteDone for seven in July 2026. Five more are scheduled before the end of February 2027. The vote is advice to the FDA, not a decision.
- FDA proposes a rule and takes public commentAs far as we can find, this hasn’t happened yet for any of them.
- FDA issues a final ruleOnly then is a peptide added to the list pharmacies are allowed to compound from.
- A licensed pharmacy compounds it with a prescriptionEven then, the peptide is still not FDA-approved, and a clinician has to prescribe it.
What this means for you
Popularity runs far ahead of the evidence for most of these. BPC-157, for example, has extensive animal research but only a handful of small human studies, and its long-term safety in people is unknown.
If you compete in sport, BPC-157 and TB-500 are banned under the World Anti-Doping Code at all times.
If you’re considering any of these for a specific problem, the useful first step is a conversation with a clinician about that problem. For many tendon, joint and gut issues there are better-proven options you can start now.
Ask Aeon about any of theseWhat the research shows, what’s legal where you are, and the questions to bring to your doctor. Aeon never gives doses or sources.
Ask Aeon in TelegramSources
- FDA Pharmacy Compounding Advisory Committee, July 23–24, 2026 meeting agenda
- McDermott Will & Schulte: committee vote details
- Frier Levitt: what the recommendations mean for compounding
- Buchanan Ingersoll & Rooney: the regulatory road after the vote
- Pharmacy Times: a pharmacist on what the vote changes
This page is general information, not legal or medical advice.